Your browser doesn't support javascript.
loading
Effect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.
Furtado, Remo H M; Fagundes, Antônio Aurélio; Oyama, Kazuma; Zelniker, Thomas A; Tang, Minao; Kuder, Julia F; Murphy, Sabina A; Hamer, Andrew; Wang, Huei; Keech, Anthony C; Giugliano, Robert P; Sabatine, Marc S; Bergmark, Brian A.
Affiliation
  • Furtado RHM; Academic Research Organization, Hospital Israelita Albert Einstein, Sao Paulo, Brazil (R.H.M.F.).
  • Fagundes AA; Instituto do Coracao (InCor), Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo, Brazil (R.H.M.F.).
  • Oyama K; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Zelniker TA; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Tang M; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Kuder JF; Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (K.O.).
  • Murphy SA; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Hamer A; Division of Cardiology, Vienna General Hospital and Medical University of Vienna, Austria (T.A.Z.).
  • Wang H; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Keech AC; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Giugliano RP; Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (R.H.M.F., A.A.F., K.O., T.A.Z., M.T., J.F.K., S.AM., R.P.G., M.S.S., B.A.B.).
  • Sabatine MS; Cardiol Therapeutics, Oakville, ON, Canada (A.H.).
  • Bergmark BA; Amgen' Thousand Oaks' CA (H.W.).
Circ Cardiovasc Interv ; 15(3): e011382, 2022 Mar.
Article in En | MEDLINE | ID: mdl-35209731
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Percutaneous Coronary Intervention Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Circ Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Percutaneous Coronary Intervention Type of study: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Circ Cardiovasc Interv Journal subject: ANGIOLOGIA / CARDIOLOGIA Year: 2022 Document type: Article